BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies

BTK inhibitors in the treatment of hematological malignancies and inflammatory diseases: mechanisms and clinical studies

Abstract Bruton’s tyrosine kinase (BTK) is an essential component of multiple signaling pathways that regulate B cell and myeloid cell proliferation, survival, and functions, making it a promising therapeutic target for various B cell malignancies and inflammatory diseases. Five small molecule inhib...

Full description

Bibliographic Details
Main Authors: Aqu Alu, Hong Lei, Xuejiao Han, Yuquan Wei, Xiawei Wei
Format: Article
Language:English
Published: BMC 2022-10-01
Series:Journal of Hematology & Oncology
Subjects:
BTK
Inhibitors
Hematological malignancies
Inflammatory diseases
Signaling pathways
Clinical trials
Online Access:https://doi.org/10.1186/s13045-022-01353-w

Internet

https://doi.org/10.1186/s13045-022-01353-w

Similar Items